Contributions
Abstract: PB2007
Type: Publication Only
Background
Anti–programmed cell death protein 1 (PD-1) antibodies are tested in patients (pts) with advanced lymphoma. Following treatment, many of those ps are likely to be candidates for allogeneic hematopoietic stem cell transplant (HSCT). Armand and Merryman demonstrated that PD-1 blockade in relapsed Hodgkin-lymphoma (cHL) followed by allo-HSCT appears to be highly efficacious but frequently complicated (22-44%) by rapid onset of severe and treatment-severe and treatment-refractory graft versus host disease (GVHD) .One-year overall and progression-free survival rates were 89% .
Aims
We report here the Institut Jules Bordet’s experience of 5 pts, 3 Hodgkin lymphoma (cHL) and 2 primary mediastinal B cell lymphoma (PMBCL) and which achieved a complete remission (CR) after antiPD1 inhibitor and or chemotherapy consolidated with allo-HSCT. All of these patients have been heavily pretreated . A sixth pt is just admitted for this procedure .
Methods
Table 1: Pts characteristics and outcome
The data incuded the data from the sixth pt just admitted will be detailled and uptdated.
Results
The time from the last Nivolumab from allo-HSCT is of 25 to 70 days. One pt died 21 days after allo-HSCT of RSV lung infection and septicemia. This patient has been treated by radiotherapy in the lung and gemcitabine few months before HSCT and that could be explained the pulmonary failure. All pts have viral and bacterial infectious complications, mainly grade I-III in severity, Two pts developed a grade II acute and one of them pts a chronic cutaneous GVHD, managed by corticoid alone.
Conclusion
AntiPD1 therapy could be represent a new opportunity to achieve a complete remission and bridge to an Allo-HSCT and may be cure heavely pretreated cHL and PMBCL pts. In our experience, all pts have presented viral and bacterial infections, mainly grade I-III in severity, as expected for these population. Two pts have a GVHD resolved with systemic and local corticoid .Four of these 5 patients are still alive and in complete remission respectively at 21, 175, 280 and 336 days after Allo-HSCT. A sixth pt is still ongoing for Haplo-ASCT
Session topic: 17. Hodgkin lymphoma – Clinical
Keyword(s): Allogeneic hematopoietic stem cell transplant, Hodgkin's disease, Immune therapy, lymphoma
Abstract: PB2007
Type: Publication Only
Background
Anti–programmed cell death protein 1 (PD-1) antibodies are tested in patients (pts) with advanced lymphoma. Following treatment, many of those ps are likely to be candidates for allogeneic hematopoietic stem cell transplant (HSCT). Armand and Merryman demonstrated that PD-1 blockade in relapsed Hodgkin-lymphoma (cHL) followed by allo-HSCT appears to be highly efficacious but frequently complicated (22-44%) by rapid onset of severe and treatment-severe and treatment-refractory graft versus host disease (GVHD) .One-year overall and progression-free survival rates were 89% .
Aims
We report here the Institut Jules Bordet’s experience of 5 pts, 3 Hodgkin lymphoma (cHL) and 2 primary mediastinal B cell lymphoma (PMBCL) and which achieved a complete remission (CR) after antiPD1 inhibitor and or chemotherapy consolidated with allo-HSCT. All of these patients have been heavily pretreated . A sixth pt is just admitted for this procedure .
Methods
Table 1: Pts characteristics and outcome
The data incuded the data from the sixth pt just admitted will be detailled and uptdated.
Results
The time from the last Nivolumab from allo-HSCT is of 25 to 70 days. One pt died 21 days after allo-HSCT of RSV lung infection and septicemia. This patient has been treated by radiotherapy in the lung and gemcitabine few months before HSCT and that could be explained the pulmonary failure. All pts have viral and bacterial infectious complications, mainly grade I-III in severity, Two pts developed a grade II acute and one of them pts a chronic cutaneous GVHD, managed by corticoid alone.
Conclusion
AntiPD1 therapy could be represent a new opportunity to achieve a complete remission and bridge to an Allo-HSCT and may be cure heavely pretreated cHL and PMBCL pts. In our experience, all pts have presented viral and bacterial infections, mainly grade I-III in severity, as expected for these population. Two pts have a GVHD resolved with systemic and local corticoid .Four of these 5 patients are still alive and in complete remission respectively at 21, 175, 280 and 336 days after Allo-HSCT. A sixth pt is still ongoing for Haplo-ASCT
Session topic: 17. Hodgkin lymphoma – Clinical
Keyword(s): Allogeneic hematopoietic stem cell transplant, Hodgkin's disease, Immune therapy, lymphoma